| Literature DB >> 22675271 |
Einor Ben-Assayag1, Milija Mijajlovic, Shani Shenhar-Tsarfaty, Irena Bova, Ludmila Shopin, Natan M Bornstein.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2012 PMID: 22675271 PMCID: PMC3362036 DOI: 10.1100/2012/532141
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Two examples illustrating degrees of LA in CT scan.
Risk factors and clinical characteristics of stroke patients with and without leukoaraiosis.
| No Leukoaraiosis | Leukoaraiosis | ||
| Index | ( | ( |
|
|
| |||
| Age, years | 62.6 ± 13.7 | 71.4 ± 11.3 | <0.001 |
| Male gender, % | 62.0 | 59.7 | 0.770 |
| BMI, kg/m2 | 27 ± 4.5 | 26.8 ± 4.5 | 0.700 |
| Diabetes mellitus, % | 22.4 | 36.1 | 0.051 |
| Hypertension, % | 54.1 | 74.6 | 0.006 |
| Hyperlipidemia, % | 45.9 | 47.9 | 0.800 |
| Current smoker, % | 29.8 | 21.4 | 0.230 |
| Ever smoker, % | 56.8 | 53.5 | 0.670 |
| Mean IMT*, mm | 0.81 ± 1.12 | 0.86 ± 1.13 | 0.002 |
| Median IMT, (IQR), mm | 0.60 (0.55–0.74) | 0.70 (0.6–0.84) | 0.002 |
| Carotid plaque/s, % | 63.3 | 82.6 | 0.007 |
|
| |||
| NIHSS | 3.9 ± 4.4 | 4.3 ± 3.4 | 0.580 |
|
| |||
| Medication use | |||
|
| |||
| Acetylsalicylic acid, % | 33.7 | 50.0 | 0.032 |
| Clopidogrel, % | 1.0 | 6.9 | 0.039 |
| Beta Blockers, % | 21.4 | 33.3 | 0.082 |
| Calcium blockers, % | 14.3 | 29.2 | 0.018 |
| ACE Inhibitors, % | 30.6 | 45.8 | 0.042 |
| ARBs, % | 1.0 | 4.2 | 0.181 |
| HMG-CoA reductaseinhibitors, % | 21.6 | 25.0 | 0.609 |
| Within lacunar strokes, % | 50.0 | 50.0 | 0.121 |
BMI indicates body mass index; IMT: intima-media thickness; NIHSS: National Institutes of Health Stroke Scale; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blockers; HMG-CoA, 3-hydroxy-3-methylglutaryl-Coenzyme A.
*Data were logarithmically transformed before analysis, presented is the geometric mean (SD).
(a) OR (95% CI) for incidence of leukoaraiosis. (b) OR (95% CI) for severity of white-matter lesions.
| Multivariate logistic regression analysis | ||
|---|---|---|
| (a) OR (95% CI) | (b) OR (95% CI) | |
| Adjusted for gender, BMI, ever smoking, hypertension, diabetes mellitus, hyperlipidemia, medication use, acetylsalicylic acid, clopidogrel, beta blockers, calcium blockers, ACE inhibitors, ARBs, HMG-CoA reductase inhibitors, stroke history, stroke etiology | for Leukoaraiosis occurrence | for severity of white matter lesions |
| Age, years | 1.043 (1.012–1.075), | 1.065 (1.027–1.103), |
| IMT above median (0.65 mm) | 2.503 (1.181–5.302), | 3.012 (1.315–6.897), |
OR indicates odds ratio; CI: confidence interval; BMI: body mass index; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blockers; HMG-CoA, 3-hydroxy-3-methylglutaryl-Coenzyme A; IMT: intima-media thickness.
Figure 2Prevalence (%) of leukoaraiosis by median of intima-media thickness (IMT). *P computed by χ 2 analysis.
Risk factors and carotid ultrasonography characteristics by severity of WMCs.
| Advanced WMCs | |||
|---|---|---|---|
| No | Yes |
| |
| ( | ( | ||
| Age, years | 63.6 ± 13.4 | 73.1 ± 10.8 | <0.001 |
| Male gender | 62.0 | 59.2 | 0.734 |
| BMI, kg/m2 | 27.1 ± 4.6 | 26.4 ± 4.1 | 0.373 |
| Diabetes mellitus, % | 26.4 | 32.7 | 0.415 |
| Hypertension, % | 57.0 | 77.1 | 0.015 |
| Hyperlipidemia, % | 46.3 | 47.9 | 0.848 |
| Current smoker, % | 29.1 | 19.1 | 0.192 |
| Ever smoker, % | 56.8 | 52.1 | 0.581 |
| Mean IMT*, mm | 0.81 ± 1.12 | 0.87 ± 1.13 | 0.003 |
| Carotid plaque/s, % | 64.9 | 87.5 | 0.004 |
| Within Lacunar strokes, % | 68.5 | 31.5 | 0.834 |
WMC indicates white matter changes; IMT: intima-media thickness.
*Data were logarithmically transformed before analysis, presented is the geometric mean (SD).